Background. Previous studies have shown impaired fibrinolysis in multiple sclerosis (MS) and implicated extracellular proteolytic enzymes as important factors in demyelinating neuroinflammatory disorders. Tissue-type plasminogen activator (t-PA) and its inhibitor (PAI-1) are key molecules in both fibrinolysis and extracellular proteolysis. In the present study, an association of the TPA Alu I/D and PAI-1 4G/5G polymorphisms with MS was analyzed within the Genomic Network for Multiple Sclerosis (GENoMS).Methods. The GENoMS includes four populations (Croatian, Slovenian, Serbian, and Bosnian and Herzegovinian) sharing the same geographic location and a similar ethnic background. A total of 885 patients and 656 ethnically matched healthy blood donors with no history of MS in their families were genotyped using PCR-RFLP.Results. TPA DD homozygosity was protective (OR = 0.79, 95% CI 0.63–0.99,) and PAI 5G5G was a risk factor for MS (OR = 1.30, 95% CI 1.01–1.66,). A significant effect of the genotype/carrier combination was detected in 5G5G/I carriers (OR = 1.39 95% CI 1.06–1.82,).Conclusions. We found a significantly harmful effect of the combination of the PAI-1 5G/5G genotype and TPA I allele on MS susceptibility, which indicates the importance of gene-gene interactions in complex diseases such as MS.
Objective: Blood‐borne angiotensinIIis generated from angiotensinogen via cleavage by renin and angiotensin‐converting enzyme (ACE), an enzymatic cascade known as the renin–angiotensin system (RAS). Several lines of evidence indicate thatACE, beyond its classical role of mediating blood pressure regulation, might contribute to the etiology of substance addictions by influencing dopaminergic signaling. A functional insertion/deletion (I/D) polymorphism of theACEgene was associated with risk for being a smoker among individuals with depression and with smoking severity in studies comprising patients with depression and healthy controls. Several reports have described significantly increasedACEactivity in cerebrospinal fluid and serum amongMSpatients. Furthermore, in our previous work withMSpatients from Croatian and Slovenian populations, we demonstrated that theACE‐I/D polymorphism contributes to an elevatedMSrisk among male patients. Here we investigated whether theACE‐I/D polymorphism might influence smoking behavior among patients withMS.Patients and Methods: Genotyping was performed in 521 patients (males/females: 139/382) using polymerase chain reaction.Results: We revealed no significant differences inACEgenotype and allele frequencies between smokers and nonsmokers and no significant association between theACE‐I/D polymorphism and either pack‐year smoking history or number of cigarettes smoked daily (p >.05, respectively).Conclusion: TheACE‐I/D polymorphism does not contribute either to risk for nicotine dependence or to smoking severity amongMSpatients. In the context of reports on theACE‐I/D polymorphism and nicotine dependence among healthy controls and patients with depression, we may speculate that the mechanism by which this polymorphism influences nicotine dependence risk differs inMScompared to depression, although not compared to a healthy population. In addition to angiotensinII, other potentialACEsubstrates, such as substance P and neurotensin, which also influence dopaminergic neurotransmission (and are proposed to be associated withMS), may deserve study in future.